Yahoo News11 天
What is duloxetine and how does it work? What to know about antidepressant recalled by FDA
A popular antidepressant, often known by the brand name Cymbalta, was recalled last week due to the presence of a potentially cancer-causing chemical. More than 233,000 bottles of duloxetine capsules ...
El Paso Times11 天
FDA recall: 230,000 bottles of anti-depressant Cymbalta over cancer risk. What to know
A nationwide recall of more than 233,000 bottles of duloxetine, an anti-depressant, has been announced by the Food and Drug Administration for possibly containing a chemical increasing the risk of ...
Health.com14 天
Duloxetine Recall: FDA Sets Second-Highest Risk Level for Antidepressants Containing ...
Korin Miller is a writer specializing in general wellness, sexual health and relationships, shopping, and lifestyle trends, with work appearing in Women’s Health, Self, Prevention, Daily Beast ...
FDA Duloxetine recall flags 7,100+ bottles of generic Cymbalta antidepressants
The U.S. Food and Drug Administration announced a Class II recall for more than 7,100 bottles of Duloxetine — a generic ...
Duloxetine antidepressant recalled over presence of toxic chemical
Thousands of bottles of the antidepressant duloxetine, which is sold under the brand name Cymbalta, have been recalled due to ...
USA Today11 天
FDA recall: More than 233,000 bottles of antidepressant could contain cancerous chemical
The U.S. Food and Drug Administration classified capsules of duloxetine, sold by New Jersey-based company Rising Pharmaceuticals, as a Class II risk on Dec. 5. The risk level is the FDA's second ...
as.com12 天
Commonly prescribed antidepressant Duloxetine recalled due to cancer risk: Products affected
The Food and Drug Administration has issued a recall on the antidepressant Duloxetine due to fears it could contain a known cancer-causing agent called N-nitroso-duloxetine. The drug’s ...
Austin American-Statesman10 天
FDA recalls more than 233,000 bottles of antidepressant over possible cancerous chemical
The U.S. Food and Drug Administration classified capsules of duloxetine, sold by New Jersey-based company Rising Pharmaceuticals, as a Class II risk on Dec. 5. The risk level is the FDA's second ...